AU2011380510B2 - Methods for treating gout flares - Google Patents

Methods for treating gout flares Download PDF

Info

Publication number
AU2011380510B2
AU2011380510B2 AU2011380510A AU2011380510A AU2011380510B2 AU 2011380510 B2 AU2011380510 B2 AU 2011380510B2 AU 2011380510 A AU2011380510 A AU 2011380510A AU 2011380510 A AU2011380510 A AU 2011380510A AU 2011380510 B2 AU2011380510 B2 AU 2011380510B2
Authority
AU
Australia
Prior art keywords
compound
gout
subject
acid
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011380510A
Other languages
English (en)
Other versions
AU2011380510A1 (en
Inventor
Brian Edward LAVAN
Charles A. Mcwherter
Brian K. Roberts
Gopal Chandra SAHA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Diatex Inc
CymaBay Therapeutics Inc
Original Assignee
Diatex Inc
CymaBay Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diatex Inc, CymaBay Therapeutics Inc filed Critical Diatex Inc
Publication of AU2011380510A1 publication Critical patent/AU2011380510A1/en
Assigned to CYMABAY THERAPEUTICS, INC. reassignment CYMABAY THERAPEUTICS, INC. Amend patent request/document other than specification (104) Assignors: METABOLEX, INC.
Application granted granted Critical
Publication of AU2011380510B2 publication Critical patent/AU2011380510B2/en
Assigned to DIATEX, INC., CYMABAY THERAPEUTICS, INC. reassignment DIATEX, INC. Request for Assignment Assignors: CYMABAY THERAPEUTICS, INC.
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2011380510A 2011-11-04 2011-11-04 Methods for treating gout flares Ceased AU2011380510B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2011/059433 WO2013066353A1 (en) 2011-11-04 2011-11-04 Methods for treating gout flares

Publications (2)

Publication Number Publication Date
AU2011380510A1 AU2011380510A1 (en) 2014-05-29
AU2011380510B2 true AU2011380510B2 (en) 2016-05-12

Family

ID=48192537

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011380510A Ceased AU2011380510B2 (en) 2011-11-04 2011-11-04 Methods for treating gout flares

Country Status (18)

Country Link
EP (1) EP2775836B8 (enExample)
JP (1) JP6008974B2 (enExample)
KR (1) KR101848121B1 (enExample)
CN (2) CN109045009A (enExample)
AU (1) AU2011380510B2 (enExample)
BR (1) BR112014010729A2 (enExample)
CA (1) CA2859693C (enExample)
CL (1) CL2014001157A1 (enExample)
DK (1) DK2775836T3 (enExample)
EA (1) EA201490928A1 (enExample)
ES (1) ES2698396T3 (enExample)
IL (1) IL232384A (enExample)
MX (1) MX357510B (enExample)
NZ (1) NZ624726A (enExample)
PH (1) PH12014500990A1 (enExample)
PL (1) PL2775836T3 (enExample)
SG (1) SG11201401981TA (enExample)
WO (1) WO2013066353A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ562292A (en) 2005-04-11 2009-11-27 Savient Pharmaceuticals Inc Variant forms of urate oxidase and use thereof
KR101861547B1 (ko) 2009-06-25 2018-07-02 크레알타 파마슈티칼스 엘엘씨 페길화된 유리카아제 치료 중에 혈청 요산을 모니터링하여 주입 반응의 위험성 및 반응의 항체­매개 상실을 예측하는 방법 및 키트
JP2013542838A (ja) 2010-11-16 2013-11-28 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー ドライアイを治療するためのシステムおよび方法
CN104602686A (zh) * 2012-04-13 2015-05-06 西玛贝医药公司 利用卤芬酯或卤芬酸以及抗炎剂治疗痛风患者中高尿酸血症的方法
EP3538135A4 (en) * 2016-11-11 2020-07-29 Horizon Pharma Rheumatology LLC POLYTHERAPIES OF PREDNISONE AND URICASE MOLECULES AND THEIR USES
US20200237881A1 (en) 2019-01-30 2020-07-30 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
EP3701952A4 (en) * 2017-10-26 2021-06-30 Otsuka Pharmaceutical Co., Ltd. INOSITE PHOSPHATE COMPOSITION
CN109223707B (zh) * 2018-09-13 2020-12-08 中国药科大学 一种尿酸酶外用凝胶制剂、其制备方法及用途
CN114028584B (zh) * 2021-11-18 2023-09-05 辽宁万嘉医药科技有限公司 一种降尿酸的多酚多元环糊精包合物及其制备方法
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers
KR20250085216A (ko) 2023-12-05 2025-06-12 인제대학교 산학협력단 알코올 스프레이를 활용한 환자 냉각장치

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613802B1 (en) * 1999-06-04 2003-09-02 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US20110268801A1 (en) * 2007-11-27 2011-11-03 Ardea Biosciences, Inc. Novel compounds and compositions and methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6624194B1 (en) 1999-06-04 2003-09-23 Metabolex, Inc. Use of (−) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
JP2008533206A (ja) * 2005-03-21 2008-08-21 メタボレックス インコーポレーティッド 代謝、炎症、および心血管障害の処置における浮腫を回避するための方法
CN102014898B (zh) * 2008-04-30 2013-01-23 维尔斯达医疗公司 用于减少尿酸的四唑化合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613802B1 (en) * 1999-06-04 2003-09-02 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US20110268801A1 (en) * 2007-11-27 2011-11-03 Ardea Biosciences, Inc. Novel compounds and compositions and methods of use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BLUHM G.B. et al, "A Double-blind Study Comparing Halofenate with Probenecid in Gout", Arthritis & Rheumatism, 1 January 1975, Vol. 18, No. 4, pages 388-389 *
METABOLEX INITIATES PHASE 2 TRIAL OF ARHALOFENATE Potential Best-in-Class URICOSURIC Agent for the Treatment of Gout" published on 20 June 2011 *
SCHLESINGER N. et al., "Managements of Acute and Chronic Gouty Artritis", Drugs, 1 January 2004, Vol. 64, No. 21, pages 2399-2416 *

Also Published As

Publication number Publication date
ES2698396T3 (es) 2019-02-04
MX357510B (es) 2018-07-12
CL2014001157A1 (es) 2015-01-16
PL2775836T3 (pl) 2019-02-28
JP6008974B2 (ja) 2016-10-19
JP2014532760A (ja) 2014-12-08
EP2775836B8 (en) 2018-10-24
WO2013066353A1 (en) 2013-05-10
PH12014500990A1 (en) 2014-08-04
EP2775836B1 (en) 2018-09-12
CA2859693A1 (en) 2013-05-10
KR20140121384A (ko) 2014-10-15
CN109045009A (zh) 2018-12-21
MX2014005398A (es) 2015-04-08
IL232384A (en) 2017-10-31
NZ624726A (en) 2016-01-29
EP2775836A1 (en) 2014-09-17
CN104066324A (zh) 2014-09-24
DK2775836T3 (en) 2018-12-03
AU2011380510A1 (en) 2014-05-29
EP2775836A4 (en) 2015-05-20
SG11201401981TA (en) 2014-05-29
BR112014010729A2 (pt) 2018-03-20
CA2859693C (en) 2018-05-22
EA201490928A1 (ru) 2014-11-28
IL232384A0 (en) 2014-06-30
KR101848121B1 (ko) 2018-04-11

Similar Documents

Publication Publication Date Title
AU2011380510B2 (en) Methods for treating gout flares
US20180055803A1 (en) Methods for Treating Gout Flares
US10137112B2 (en) Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent
AU2011380507B2 (en) Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent
AU2011380509B2 (en) Methods for treating gout in patient subpopulations
AU2013245675B2 (en) Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent
JP6368756B2 (ja) ハロフェナートまたはハロフェン酸および第２の尿酸低下薬を用いる痛風に罹っている患者の高尿酸血症の治療方法
JP6192142B2 (ja) 痛風発赤の治療方法
US20130302305A1 (en) Methods for Treating Gout in Patients Subpopulations

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: DIATEX, INC.

Free format text: FORMER OWNER(S): CYMABAY THERAPEUTICS, INC.

Owner name: CYMABAY THERAPEUTICS, INC.

Free format text: FORMER OWNER(S): CYMABAY THERAPEUTICS, INC.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired